Phase II trial of FOLFOXIRI + Bevacizumab in patients with untreated metastatic colorectal cancer - Bevacizumab + Triplet treatment for untreated metastatic colorectal cancer

Translational Research Informatics Center, Foundation for Biomedical Research and Innovation0 个研究点目标入组 45 人开始时间: 2015年4月19日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Vermiform appendix cancer and proctos cancer. 2. Administration of blood products/ G-CSF, and blood transfusion within 14 days. 3. Synchronous multiple malignancy or metachronous multiple malignancy within 5 years disease free interval. 4. HBs-Ag(+), or HCV-Ab(+). 5. History of severe allergy. 6. Sensory alteration or paresthesia interfering with function. 7. Prior radiotherapy for ilium and abdomen. 8. Infectious disease. 9. Uncontrolled diarrhea. 10. Ileus or bowel obstruction. 11. Interstitial lung disease or pulmonary fibrosis. 12. Malignant coelomic fluid required drainage. 13. Administration of atazanavir sulfate. 14. Heart disease to be clinically problem. 15. Major surgical procedure or intestinal resection within 28 days prior to enrollment or colostomy within 14 days prior to enrollment. 16. Known brain metastasis or strongly suspected of brain metastasis. 17. History of a thromboembolic disease. 18. Receiving anti-platelet drugs. 19. Poorly controlled gastrointestinal ulcer. 20. History of intestinal perforation within 12 months. 21. Poorly controlled hypertension. 22. Poorly controlled diabetes mellitus. 23. Severe mental disorders. 24. Women's pregnant or nursing, men/women who want to give birth or no intention to contraception. 25. Any other cases who are regarded as inadequate for study enrollment by investigators.

发起方

Translational Research Informatics Center, Foundation for Biomedical Research and Innovation